Works matching IS 02780232 AND DT 2022 AND VI 40

Results: 131
    1

    Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: Report from the prospective international T‐cell lymphoma project.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 953, doi. 10.1002/hon.3074
    By:
    • Chiattone, Carlos;
    • Civallero, Monica;
    • Fischer, Thais;
    • Miranda, Eliana;
    • Manni, Martina;
    • Zing, Natalia P. C.;
    • Pileri, Stefano A.;
    • Montoto, Silvia;
    • Horwitz, Steven M.;
    • Cabrera, Maria Elena;
    • De Souza, Carmino A.;
    • Nagler, Arnon;
    • Luminari, Stefano;
    • Ferreri, Andrés J. M.;
    • Carson, Kenneth R.;
    • Re, Alessandro;
    • Rigacci, Luigi;
    • Nassi, Luca;
    • Stepanishyna, Yana;
    • Federico, Massimo
    Publication type:
    Article
    2
    3

    CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 876, doi. 10.1002/hon.3072
    By:
    • Sakamoto, Yuma;
    • Ishida, Takashi;
    • Masaki, Ayako;
    • Murase, Takayuki;
    • Ohtsuka, Eiichi;
    • Takeshita, Morishige;
    • Muto, Reiji;
    • Iwasaki, Hiromi;
    • Ito, Asahi;
    • Kusumoto, Shigeru;
    • Nakano, Nobuaki;
    • Tokunaga, Masahito;
    • Yonekura, Kentaro;
    • Tashiro, Yukie;
    • Iida, Shinsuke;
    • Utsunomiya, Atae;
    • Ueda, Ryuzo;
    • Inagaki, Hiroshi
    Publication type:
    Article
    4
    5
    6

    The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 962, doi. 10.1002/hon.3063
    By:
    • De Luca, Giuseppa;
    • Cerruti, Giannamaria;
    • Lastraioli, Sonia;
    • Conte, Romana;
    • Ibatici, Adalberto;
    • Di Felice, Nikki;
    • Morabito, Fortunato;
    • Monti, Paola;
    • Fronza, Gilberto;
    • Matis, Serena;
    • Colombo, Monica;
    • Fabris, Sonia;
    • Ciarrocchi, Alessia;
    • Neri, Antonino;
    • Menichini, Paola;
    • Ferrarini, Manlio;
    • Nozza, Paolo;
    • Fais, Franco;
    • Cutrona, Giovanna;
    • Dono, Mariella
    Publication type:
    Article
    7
    8

    Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 857, doi. 10.1002/hon.3060
    By:
    • Lanza, Francesco;
    • Monaco, Federica;
    • Ciceri, Fabio;
    • Cairoli, Roberto;
    • Sacchi, Maria Vittoria;
    • Guidetti, Anna;
    • Marchetti, Monia;
    • Massaia, Massimo;
    • Arcaini, Luca;
    • Krampera, Mauro;
    • Mohamed, Sara;
    • Gherlinzoni, Filippo;
    • Mecucci, Cristina;
    • Gentile, Massimo;
    • Romano, Ilaria;
    • Venditti, Adriano;
    • Ruggeri, Marco;
    • Ferrero, Dario;
    • Coviello, Elisa;
    • Fabbri, Elisabetta
    Publication type:
    Article
    9

    Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1076, doi. 10.1002/hon.3058
    By:
    • Okada, Yosuke;
    • Takenaka, Katsuto;
    • Murata, Makoto;
    • Shimazu, Yutaka;
    • Tachibana, Takayoshi;
    • Ozawa, Yukiyasu;
    • Uchida, Naoyuki;
    • Wakayama, Toshio;
    • Doki, Noriko;
    • Sugio, Yasuhiro;
    • Tanaka, Masatsugu;
    • Masuko, Masayoshi;
    • Kobayashi, Hikaru;
    • Ino, Kazuko;
    • Ishikawa, Jun;
    • Nakamae, Hirohisa;
    • Matsuoka, Ken‐ichi;
    • Kanda, Yoshinobu;
    • Fukuda, Takahiro;
    • Atsuta, Yoshiko
    Publication type:
    Article
    10
    11

    Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup>) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 930, doi. 10.1002/hon.3054
    By:
    • Shi, Yuankai;
    • Zhang, Qingyuan;
    • Hong, Xiaonan;
    • Wang, Zhen;
    • Gao, Yuhuan;
    • Zou, Liqun;
    • Cen, Hong;
    • Gui, Lin;
    • Li, Yufu;
    • Feng, Jifeng;
    • Wang, Zhao;
    • Zhang, Mingzhi;
    • Jin, Chuan;
    • Zhang, Weihua;
    • Hu, Jianda;
    • Zheng, Chengyun;
    • Zheng, Zhendong;
    • Zhang, Liling;
    • Chen, Shaoshui;
    • Huang, Yunhong
    Publication type:
    Article
    12

    Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 922, doi. 10.1002/hon.3053
    By:
    • Hoffmann, Christian;
    • Rating, Philipp;
    • Bechrakis, Nikolaos;
    • Eckstein, Anja;
    • Sokolenko, Ekaterina;
    • Jabbarli, Leyla;
    • Westekemper, Henrike;
    • Mohr, Christopher;
    • Schmeling, Claus;
    • Huettmann, Andreas;
    • von Tresckow, Julia;
    • Göricke, Sophia;
    • Deuschl, Cornelius;
    • Johansson, Patricia;
    • Poettgen, Christoph;
    • Gauler, Thomas;
    • Guberina, Nika;
    • Moliavi, Sourour;
    • Stuschke, Martin;
    • Guberina, Maja
    Publication type:
    Article
    13

    Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1041, doi. 10.1002/hon.3046
    By:
    • Morita‐Fujita, Mari;
    • Arai, Yasuyuki;
    • Kondo, Tadakazu;
    • Harada, Kaito;
    • Uchida, Naoyuki;
    • Toya, Takashi;
    • Ozawa, Yukiyasu;
    • Fukuda, Takahiro;
    • Ota, Shuichi;
    • Onizuka, Makoto;
    • Kanda, Yoshinobu;
    • Maruyama, Yumiko;
    • Takada, Satoru;
    • Kawakita, Toshiro;
    • Ara, Takahide;
    • Ichinohe, Tatsuo;
    • Kimura, Takafumi;
    • Atsuta, Yoshiko;
    • Kako, Shinichi
    Publication type:
    Article
    14
    15
    16

    Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 846, doi. 10.1002/hon.3048
    By:
    • Zappasodi, Patrizia;
    • Cattaneo, Chiara;
    • Valeria Ferretti, Virginia;
    • Mina, Roberto;
    • José María Ferreri, Andrés;
    • Merli, Francesco;
    • Oberti, Margherita;
    • Krampera, Mauro;
    • Romano, Alessandra;
    • Zerbi, Caterina;
    • Ferrari, Jacqueline;
    • Cavo, Michele;
    • Salvini, Marco;
    • Bertù, Lorenza;
    • Stefano Fracchiolla, Nicola;
    • Marchesi, Francesco;
    • Massaia, Massimo;
    • Marasco, Vincenzo;
    • Cairoli, Roberto;
    • Maria Scattolin, Anna
    Publication type:
    Article
    17

    NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 864, doi. 10.1002/hon.3050
    By:
    • Vegliante, Maria Carmela;
    • Mazzara, Saveria;
    • Zaccaria, Gian Maria;
    • De Summa, Simona;
    • Esposito, Flavia;
    • Melle, Federica;
    • Motta, Giovanna;
    • Sapienza, Maria Rosaria;
    • Opinto, Giuseppina;
    • Volpe, Giacomo;
    • Bucci, Antonella;
    • Gargano, Grazia;
    • Enjuanes, Anna;
    • Tabanelli, Valentina;
    • Fiori, Stefano;
    • Minoia, Carla;
    • Clemente, Felice;
    • Negri, Antonio;
    • Gulino, Alessandro;
    • Morello, Gaia
    Publication type:
    Article
    18
    19

    Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 976, doi. 10.1002/hon.3044
    By:
    • Younan, Nadia;
    • Soussain, Carole;
    • Choquet, Sylvain;
    • Cassoux, Nathalie;
    • Touitou, Valérie;
    • Schmitt, Anna;
    • Chinot, Olivier;
    • Oberic, Lucie;
    • Damaj, Gandhi;
    • Houot, Roch;
    • Ghesquières, Hervé;
    • Laribi, Kamel;
    • Ahle, Guido;
    • Taillandier, Luc;
    • Paillassa, Jérôme;
    • Gyan, Emmanuel;
    • Jardin, Fabrice;
    • Delwail, Vincent;
    • Marolleau, Jean‐Pierre;
    • Tempescul, Adrian
    Publication type:
    Article
    20

    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1020, doi. 10.1002/hon.3038
    By:
    • Facon, Thierry;
    • Moreau, Philippe;
    • Martin, Thomas G.;
    • Spicka, Ivan;
    • Oriol, Albert;
    • Koh, Youngil;
    • Lim, Andrew;
    • Mikala, Gabor;
    • Rosiñol, Laura;
    • Yağci, Münci;
    • Cavo, Michele;
    • Yong, Kwee;
    • Risse, Marie‐Laure;
    • Asset, Gaëlle;
    • Schwab, Sandrine;
    • Martinez, Gracia
    Publication type:
    Article
    21

    Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1094, doi. 10.1002/hon.3043
    By:
    • Takahashi, Hiromichi;
    • Miura, Katsuhiro;
    • Nakagawa, Masaru;
    • Nishimaki, Haruna;
    • Ito, Shun;
    • Nukariya, Hironao;
    • Kurihara, Kazuya;
    • Endo, Toshihide;
    • Koike, Takashi;
    • Hamada, Takashi;
    • Iizuka, Kazuhide;
    • Ohatake, Shimon;
    • Iriyama, Noriyoshi;
    • Nakayama, Tomohiro;
    • Masuda, Shinobu;
    • Hatta, Yoshihiro;
    • Nakamura, Hideki
    Publication type:
    Article
    22
    23
    24

    Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1105, doi. 10.1002/hon.3039
    By:
    • Condoluci, Adalgisa;
    • Milan, Lisa;
    • Forestieri, Gabriela;
    • Terzi di Bergamo, Lodovico;
    • Spina, Valeria;
    • Bruscaggin, Alessio;
    • Deambrogi, Clara;
    • Moia, Riccardo;
    • Deodato, Marina;
    • Fahrni, Gaby;
    • Mattarucchi, Roberta;
    • Merli, Michele;
    • Gerber, Bernhard;
    • Stussi, Georg;
    • Passamonti, Francesco;
    • Gregor, Michael;
    • Tedeschi, Alessandra;
    • Gaidano, Gianluca;
    • Rossi, Davide;
    • Ceriani, Luca
    Publication type:
    Article
    25
    26
    27

    Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 987, doi. 10.1002/hon.3041
    By:
    • Botta, Cirino;
    • Gigliotta, Emilia;
    • Paiva, Bruno;
    • Anselmo, Rita;
    • Santoro, Marco;
    • Otero, Paula Rodriguez;
    • Carlisi, Melania;
    • Conticello, Concetta;
    • Romano, Alessandra;
    • Solimando, Antonio Giovanni;
    • Cerchione, Claudio;
    • Vià, Matteo Da;
    • Bolli, Niccolò;
    • Correale, Pierpaolo;
    • Di Raimondo, Francesco;
    • Gentile, Massimo;
    • San Miguel, Jesus;
    • Siragusa, Sergio
    Publication type:
    Article
    28

    Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1009, doi. 10.1002/hon.3035
    By:
    • Martino, Enrica Antonia;
    • Conticello, Concetta;
    • Zamagni, Elena;
    • Pavone, Vincenzo;
    • Palmieri, Salvatore;
    • Musso, Maurizio;
    • Tacchetti, Paola;
    • Mele, Anna;
    • Catalano, Lucio;
    • Vigna, Ernesto;
    • Bruzzese, Antonella;
    • Mendicino, Francesco;
    • Botta, Cirino;
    • Vincelli, Iolanda Donatella;
    • Farina, Giuliana;
    • Barone, Marialucia;
    • Cangialosi, Clotilde;
    • Mancuso, Katia;
    • Rizziello, Ilaria;
    • Rocchi, Serena
    Publication type:
    Article
    29

    Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 1100, doi. 10.1002/hon.3032
    By:
    • Forestieri, Gabriela;
    • Terzi di Bergamo, Lodovico;
    • Deodato, Marina;
    • Frustaci, Anna Maria;
    • Moia, Riccardo;
    • Deambrogi, Clara;
    • Rasi, Silvia;
    • Autore, Francesco;
    • Merli, Michele;
    • Mattarucchi, Roberta;
    • Fahrni, Gaby;
    • Scarfo', Lydia;
    • Gussetti, Daniela;
    • Bulian, Pietro;
    • Zanatta, Annagiulia;
    • Spina, Valeria;
    • Bruscaggin, Alessio;
    • Pini, Katia;
    • Piffaretti, Deborah;
    • Pirosa, Maria Cristina
    Publication type:
    Article
    30
    31
    32
    33

    Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 645, doi. 10.1002/hon.3025
    By:
    • Durmo, Rexhep;
    • Donati, Benedetta;
    • Rebaud, Louis;
    • Cottereau, Anne Segolene;
    • Ruffini, Alessia;
    • Nizzoli, Maria Elena;
    • Ciavarella, Sabino;
    • Vegliante, Maria Carmela;
    • Nioche, Christophe;
    • Meignan, Michel;
    • Merli, Francesco;
    • Versari, Annibale;
    • Ciarrocchi, Alessia;
    • Buvat, Irene;
    • Luminari, Stefano
    Publication type:
    Article
    34
    35
    36
    37
    38
    39

    Issue Information.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 819, doi. 10.1002/hon.2893
    Publication type:
    Article
    40
    41

    Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 704, doi. 10.1002/hon.3031
    By:
    • Bruzzese, Antonella;
    • Derudas, Daniele;
    • Galli, Monica;
    • Martino, Enrica Antonia;
    • Rocco, Stefano;
    • Conticello, Concetta;
    • Califano, Catello;
    • Giuliani, Nicola;
    • Mangiacavalli, Silvia;
    • Farina, Giuliana;
    • Lombardo, Alessandra;
    • Brunori, Marino;
    • Rossi, Elena;
    • Antonioli, Elisabetta;
    • Ria, Roberto;
    • Zambello, Renato;
    • Di Renzo, Nicola;
    • Mele, Giuseppe;
    • Marcacci, Gianpaolo;
    • Pietrantuono, Giuseppe
    Publication type:
    Article
    42

    Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 577, doi. 10.1002/hon.3030
    By:
    • Kumari, Sarita;
    • Ali, M. Shadab;
    • Singh, Jay;
    • Arora, Mohit;
    • Verma, Deepak;
    • Pandey, Avanish Kumar;
    • Benjamin, Mercilena;
    • Bakhshi, Sameer;
    • Palanichamy, Jayanth Kumar;
    • Sharma, Atul;
    • Singh, Inder;
    • Tanwar, Pranay;
    • Singh, Amar Ranjan;
    • Pushpam, Deepam;
    • Qamar, Imteyaz;
    • Chopra, Anita
    Publication type:
    Article
    43

    Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 734, doi. 10.1002/hon.3029
    By:
    • Sartor, Chiara;
    • Arpinati, Mario;
    • Chirumbolo, Gabriella;
    • Dozza, Luca;
    • Cristiano, Gianluca;
    • Nanni, Jacopo;
    • Marconi, Giovanni;
    • Robustelli, Valentina;
    • Vigliotta, Ilaria;
    • Parisi, Sarah;
    • Terragna, Carolina;
    • Testoni, Nicoletta;
    • Paolini, Stefania;
    • Martinelli, Giovanni;
    • Curti, Antonio;
    • Cavo, Michele;
    • Papayannidis, Cristina
    Publication type:
    Article
    44

    Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 609, doi. 10.1002/hon.3028
    By:
    • Rigacci, Luigi;
    • Battistini, Roberta;
    • Kovalchuk, Sofia;
    • Zoli, Valerio;
    • Puccini, Benedetta;
    • Evangelista, Andrea;
    • Arcaini, Luca;
    • Flenghi, Leonardo;
    • Visco, Carlo;
    • Mian, Michael;
    • Di Rocco, Alice;
    • Peracchio, Claudia;
    • Gotti, Manuel;
    • Tisi, Maria Chiara;
    • Palombi, Francesca;
    • Pozzi, Samantha;
    • Gioia, Daniela;
    • Viero, Piera;
    • Martelli, Maurizio
    Publication type:
    Article
    45

    Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 588, doi. 10.1002/hon.3027
    By:
    • Piñeyroa, Juan A.;
    • Magnano, Laura;
    • Rivero, Andrea;
    • Rivas‐Delgado, Alfredo;
    • Nadeu, Ferran;
    • Correa, Juan Gonzalo;
    • Giné, Eva;
    • Villamor, Neus;
    • Filella, Xavier;
    • Colomer, Dolors;
    • López, Mònica;
    • López‐Oreja, Irene;
    • Costa, Dolors;
    • Aymerich, Marta;
    • Beà, Sílvia;
    • López‐Guillermo, Armando;
    • Campo, Elías;
    • Delgado, Julio;
    • Mozas, Pablo
    Publication type:
    Article
    46

    Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper.

    Published in:
    Hematological Oncology, 2022, v. 40, n. 4, p. 505, doi. 10.1002/hon.3013
    By:
    • Bailly, Sarah;
    • Cartron, Guillaume;
    • Chaganti, Sridhar;
    • Córdoba, Raul;
    • Corradini, Paolo;
    • Düll, Johannes;
    • Ferrarini, Isacco;
    • Osborne, Wendy;
    • Rosenwald, Andreas;
    • Sancho, Juan‐Manuel;
    • Tilly, Hervé;
    • Van Den Neste, Eric;
    • Viardot, Andreas;
    • Visco, Carlo
    Publication type:
    Article
    47
    48
    49
    50